In the June issue of EMBO (European Molecular Biology Organization) journal vol. 13, 472, the editor discusses the impact of aneuploidy (the deviation from a haploid chromosome number—such as defects in mitotic checkpoint proteins or sister chromatid cohesion, incorrect or hyperstabilized chromosome-spindle attachments, centrosome amplification or defects in cytokinesis that contribute to the occurrence of some of the types of cancer. It is expected that further emphasis in this line of research will shed enough light for suitable drug discovery alleviating some of the pernicious metabolic disorders, namely cancer.